StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax r&d expenses

Research and development expenses are spending on new products and technology.

Novavax's R&D Expenses for the twelve months ending Jun 30, 2026 was $340.32M, down 5.4% year over year. For fiscal 2025 it was $342.32M, down 12.5% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $2.53B in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$342.32M-12.5%
FY2024Dec 31, 2024$391.17M-47.0%
FY2023Dec 31, 2023$737.50M-40.3%
FY2022Dec 31, 2022$1.24B-51.3%
FY2021Dec 31, 2021$2.53B+239.3%
FY2020Dec 31, 2020$747.03M+556.2%
FY2019Dec 31, 2019$113.84M-34.5%
FY2018Dec 31, 2018$173.80M+3.2%
FY2017Dec 31, 2017$168.44M-29.2%
FY2016Dec 31, 2016$237.94M+46.3%
FY2015Dec 31, 2015$162.64M+72.3%
FY2014Dec 31, 2014$94.42M+61.3%
FY2013Dec 31, 2013$58.53M+117.5%
FY2012Dec 31, 2012$26.91M+46.5%
FY2011Dec 31, 2011$18.36M-34.5%
FY2010Dec 31, 2010$28.03M+8.7%
FY2009Dec 31, 2009$25.78M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$70.69M-10.8%
Q1 FY2026Mar 31, 2026$95.47M+7.3%
Q4 FY2025Dec 31, 2025$75.88M-27.3%
Q3 FY2025Sep 30, 2025$98.27M+12.7%
Q2 FY2025Jun 30, 2025$79.23M-25.9%
Q1 FY2025Mar 31, 2025$88.94M-4.0%
Q4 FY2024Dec 31, 2024$104.38M-36.6%
Q3 FY2024Sep 30, 2024$87.16M-17.9%
Q2 FY2024Jun 30, 2024$106.95M-51.3%
Q1 FY2024Mar 31, 2024$92.68M-62.5%
Q4 FY2023Dec 31, 2023$164.70M-36.1%
Q3 FY2023Sep 30, 2023$106.23M-65.1%
Q2 FY2023Jun 30, 2023$219.48M-24.2%
Q1 FY2023Mar 31, 2023$247.10M-35.6%
Q4 FY2022Dec 31, 2022$257.85M-73.2%
Q3 FY2022Sep 30, 2022$304.30M-25.5%
Q2 FY2022Jun 30, 2022$289.65M-49.2%
Q1 FY2022Mar 31, 2022$383.48M-35.3%
Q4 FY2021Dec 31, 2021$962.96M+140.0%
Q3 FY2021Sep 30, 2021$408.20M+38.8%
Q2 FY2021Jun 30, 2021$570.69M+1537.7%
Q1 FY2021Mar 31, 2021$592.67M+3408.0%
Q4 FY2020Dec 31, 2020$401.20M+1267.4%
Q3 FY2020Sep 30, 2020$294.09M+1480.2%
Q2 FY2020Jun 30, 2020$34.85M+14.6%
Q1 FY2020Mar 31, 2020$16.90M-52.4%
Q4 FY2019Dec 31, 2019$29.34M-32.4%
Q3 FY2019Sep 30, 2019$18.61M-55.0%
Q2 FY2019Jun 30, 2019$30.42M-31.7%
Q1 FY2019Mar 31, 2019$35.47M-20.3%
Q4 FY2018Dec 31, 2018$43.42M-12.6%
Q3 FY2018Sep 30, 2018$41.33M-1.3%
Q2 FY2018Jun 30, 2018$44.54M+13.4%
Q1 FY2018Mar 31, 2018$44.51M+18.2%
Q4 FY2017Dec 31, 2017$49.66M-2.8%
Q3 FY2017Sep 30, 2017$41.86M-21.0%
Q2 FY2017Jun 30, 2017$39.26M–
Q1 FY2017Mar 31, 2017$37.65M–
Q4 FY2016Dec 31, 2016$51.10M–
Q3 FY2016Sep 30, 2016$52.98M–

More Novavax figures

See a number that looks wrong?